NCT05567679View on ClinicalTrials.gov

A Study of Tazemetostat (Tazverik) Before Prostatectomy in Men With Prostate Cancer

EARLY_PHASE1WithdrawnINTERVENTIONAL
0
Timeline

Start Date

December 31, 2023

Primary Completion Date

December 31, 2025

Study Completion Date

December 31, 2025

Conditions
Prostate Cancer
Interventions
DRUG

Tazverik

Tazemetostat (Tazverik) 200 mg oral tablets; 800 mg by mouth twice daily for 28 days

Trial Locations (1)

90048

Cedars-Sinai Medical Center, Los Angeles

Sponsors

Collaborators (1)

Epizyme, Inc.
All Listed Sponsors
collaborator

Epizyme, Inc.

INDUSTRY

lead

Edwin Posadas, MD

OTHER

NCT05567679 - A Study of Tazemetostat (Tazverik) Before Prostatectomy in Men With Prostate Cancer | Biotech Hunter | Biotech Hunter